Search Results
Departments of Biochemistry, Obstetrics and Gynecology and Women's Health, Medicine, Department of Pediatrics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, F312, Bronx, New York 10461, USA
Departments of Biochemistry, Obstetrics and Gynecology and Women's Health, Medicine, Department of Pediatrics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, F312, Bronx, New York 10461, USA
Search for other papers by Maureen J Charron in
Google Scholar
PubMed
Search for other papers by Patricia M Vuguin in
Google Scholar
PubMed
associated with an increase in the number of pancreatic islets and an increase in the number of somatostatin cells without altering insulin cell mass. Lack of glucagon signaling is also associated with a profound glucagon cell hyperplasia. A subset of those
Search for other papers by Bert De Groef in
Google Scholar
PubMed
Search for other papers by Sylvia V H Grommen in
Google Scholar
PubMed
Search for other papers by Veerle M Darras in
Google Scholar
PubMed
. Corticotrophin-releasing hormone (CRH) is also a potent stimulator of TSH secretion ( Geris et al. 1996 , 2003 b ), whereas somatostatin (SRIH) was shown to inhibit TSH release at the level of the pituitary ( Geris et al. 2003 a , 2003 b ). The inhibition
Physiology and Pharmacology and
Medicine, University of Western Ontario, Canada
Children’s Health Research Institute, London, Ontario, Canada
Search for other papers by E N Fazio in
Google Scholar
PubMed
Physiology and Pharmacology and
Medicine, University of Western Ontario, Canada
Children’s Health Research Institute, London, Ontario, Canada
Search for other papers by M Everest in
Google Scholar
PubMed
Physiology and Pharmacology and
Medicine, University of Western Ontario, Canada
Children’s Health Research Institute, London, Ontario, Canada
Search for other papers by R Colman in
Google Scholar
PubMed
Physiology and Pharmacology and
Medicine, University of Western Ontario, Canada
Children’s Health Research Institute, London, Ontario, Canada
Search for other papers by R Wang in
Google Scholar
PubMed
Physiology and Pharmacology and
Medicine, University of Western Ontario, Canada
Children’s Health Research Institute, London, Ontario, Canada
Search for other papers by C L Pin in
Google Scholar
PubMed
, Vanderbilt University, Nashville, Tennessee, USA), rabbit anti-Glut-2 (1:500; Chemicon), rabbit anti-somatostatin (1:50; Chemicon) and rabbit anti-Mist1 (1:1000; Pin et al. 2001 ). In some cases, dual labeling was performed by co-incubating insulin
Search for other papers by Silvya Stuchi Maria-Engler in
Google Scholar
PubMed
Search for other papers by Maria Lúcia C Corrêa-Giannella in
Google Scholar
PubMed
Search for other papers by Letícia Labriola in
Google Scholar
PubMed
Search for other papers by Karin Krogh in
Google Scholar
PubMed
Search for other papers by Christian Colin in
Google Scholar
PubMed
Search for other papers by Fernando Henrique Lojudice in
Google Scholar
PubMed
Search for other papers by Carlos Alberto Mayora Aita in
Google Scholar
PubMed
Search for other papers by Elizabeth Maria Costa de Oliveira in
Google Scholar
PubMed
Search for other papers by Tatiana C Silveira Corrêa in
Google Scholar
PubMed
Search for other papers by Irenice Cairo da Silva in
Google Scholar
PubMed
Search for other papers by Tercio Genzini in
Google Scholar
PubMed
Search for other papers by Marcelo Perosa de Miranda in
Google Scholar
PubMed
Search for other papers by Irene Lourdes Noronha in
Google Scholar
PubMed
Search for other papers by Luciano Vilela in
Google Scholar
PubMed
Search for other papers by Cassio Negro Coimbra in
Google Scholar
PubMed
Search for other papers by Renato A Mortara in
Google Scholar
PubMed
Search for other papers by Marcos Mares Guia in
Google Scholar
PubMed
Search for other papers by Freddy Goldberg Eliaschewitz in
Google Scholar
PubMed
Search for other papers by Mari Cleide Sogayar in
Google Scholar
PubMed
islets and in long-term cultures enriched in nestin-positive cells. Low mRNA levels of insulin, glucagon and somatostatin were detected after prolonged subculturing in low serum medium without addition of differentiation-inducing factors. The attempt to
School of Applied and Engineering Physics, Cornell University, Ithaca, New York, USA
Laboratory for Nanoscale Cell Biology, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany
Search for other papers by Ying Zhao in
Google Scholar
PubMed
Laboratory for Nanoscale Cell Biology, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany
Search for other papers by Qinghua Fang in
Google Scholar
PubMed
Search for other papers by Susanne G Straub in
Google Scholar
PubMed
Laboratory for Nanoscale Cell Biology, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany
Search for other papers by Manfred Lindau in
Google Scholar
PubMed
Search for other papers by Geoffrey W G Sharp in
Google Scholar
PubMed
(NE), somatostatin, and several other agonists, prostaglandins inhibit the secretion of insulin by several mechanisms. These include (i) activation of K + channels to repolarize or hyperpolarize the cell ( Rorsman et al. 1991 , Sharp 1996
Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Research and Development, Chicago, Illinois 60612, USA
Search for other papers by E Kim in
Google Scholar
PubMed
Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Research and Development, Chicago, Illinois 60612, USA
Search for other papers by S Sohn in
Google Scholar
PubMed
Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Research and Development, Chicago, Illinois 60612, USA
Search for other papers by M Lee in
Google Scholar
PubMed
Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Research and Development, Chicago, Illinois 60612, USA
Search for other papers by J Jung in
Google Scholar
PubMed
Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Research and Development, Chicago, Illinois 60612, USA
Search for other papers by R D Kineman in
Google Scholar
PubMed
Department of Medicine, University of Illinois at Chicago and Jesse Brown VA Medical Center, Research and Development, Chicago, Illinois 60612, USA
Search for other papers by S Park in
Google Scholar
PubMed
-treated rat is more sensitive to the stimulatory actions of GHRH ( Sheppard et al. 1989 a , 1989 b ) and GH secretagogue (GHS) receptor (GHS-R) agonists (ipamorelin; Johansen et al. 2003 ) and less sensitive to the inhibitory actions of somatostatin
Search for other papers by C. J. Bailey in
Google Scholar
PubMed
Search for other papers by L. C. Wilkes in
Google Scholar
PubMed
Search for other papers by J. M. Conlon in
Google Scholar
PubMed
Search for other papers by P. H. Armstrong in
Google Scholar
PubMed
Search for other papers by K. D. Buchanan in
Google Scholar
PubMed
ABSTRACT
The release of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) by isolated mouse pancreatic islets was determined during 30-min incubations at 5.6 and 16.7 mmol glucose/l in the absence and presence of gastric inhibitory polypeptide (GIP), vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI) at concentrations of 1–1000 nmol/l. Insulin release was enhanced (>50%) by GIP (100–1000 nmol/l) and VIP (1 μmol/l) at 5.6 mmol glucose/l, but not at 16.7 mmol glucose/l. Glucagon release was increased by GIP (100–1000 nmol/l), and by VIP and PHI (1—1000 nmol/l) at both glucose concentrations in a dose-related manner (maximum increases > tenfold). Somatostatin release was similarly increased by GIP (10–1000 nmol/l) at both glucose concentrations. Only the highest concentration (1 μmol/l of PHI tested increased somatostatin release (twofold) at 5.6 mmol glucose/l, whereas PHI and VIP (1–1000 nmol/l reduced (>37%) somatostatin release at 16.7 mmol glucose/l. PP release was increased (49–58%) by 100–1000 nmol GIP/l, but was not significantly altered by VIP, and was reduced (39–56%) by PHI. The results indicate that GIP, VIP and PHI each stimulate glucagon release in a dose-related manner, but they exert discretely different effects on other islet hormones depending upon the dose and the prevailing glucose concentration.
Journal of Endocrinology (1990) 125, 375–379
Search for other papers by D. G. Lambert in
Google Scholar
PubMed
Search for other papers by T. W. Atkins in
Google Scholar
PubMed
ABSTRACT
The effects of the islet cell hormones glucagon, somatostatin-28 and pancreatic polypeptide on insulin secretion from cultured cloned pancreatic B cells (HIT-T15 and RINm5F) have been investigated. Glucagon stimulates the secretion of insulin from HIT-T15 cells in the absence and presence of glucose and from RINm5F cells in the absence and presence of glyceraldehyde. HIT-T15 cells were more sensitive to the stimulatory effect of glucagon than RINm5F cells. Somatostatin-28 and pancreatic polypeptide, both alone and in combination, reduced glucose- and glucagon-stimulated insulin release from HIT-T15 cells and glyceraldehyde- and glucagon-stimulated insulin release from RINm5F cells. HIT-T15 cells were more sensitive to the inhibitory actions of somatostatin-28 and pancreatic polypeptide than RINm5F cells. This study supports the hypothesis that insulin release from normal B cells may be modified by the paracrine activity of islet hormones, glucagon, somatostatin and pancreatic polypeptide and probably occurs before any fine tuning imposed by subsequently released insulin.
Journal of Endocrinology (1989) 121, 479–485
Search for other papers by H. Vilhardt in
Google Scholar
PubMed
Search for other papers by T. Krarup in
Google Scholar
PubMed
Search for other papers by J. J. Holst in
Google Scholar
PubMed
Search for other papers by P. Bie in
Google Scholar
PubMed
ABSTRACT
Injections and infusions of oxytocin into conscious dogs caused an increase in plasma concentrations of glucose, insulin and glucagon. When blood glucose was clamped at a raised level the injection of oxytocin still increased insulin and glucagon concentrations in plasma. Infusion of somatostatin suppressed plasma concentrations of glucagon and insulin but did not prevent oxytocin-induced increments in blood glucose. Injection of oxytocin still caused a marked release of glucagon, whereas the insulin response was greatly diminished. When endogenous insulin and glucagon secretion was suppressed by infusion of somatostatin and glucose levels were stabilized by concomitant infusions of glucagon and insulin, injections of oxytocin did not alter blood glucose concentrations. It is concluded that the increase in blood glucose following the administration of oxytocin is secondary to the release of glucagon and that oxytocin exerts a direct stimulatory effect on glucagon and possibly insulin secretion.
J. Endocr. (1986) 108, 293–298
Search for other papers by N. H. GRANT in
Google Scholar
PubMed
Search for other papers by D. SARANTAKIS in
Google Scholar
PubMed
Search for other papers by J. P. YARDLEY in
Google Scholar
PubMed
Somatostatin, the growth hormone release inhibitory hormone (Brazeau, Vale, Burgus, Ling, Butcher, Rivier & Guillemin, 1973), NH2-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-Co2H, is the first hypothalamic hormone shown unequivocally to exert a negative control over pituitary secretion. Its inhibition of growth hormone release has been confirmed in normal and diabetic men (Hansen, Ørskov, Seyer-Hansen & Lundbaek, 1973).
The present study was undertaken to determine whether somatostatin can also alter prolactin release. Cultures of secreting pituitary cells offer the least ambiguous model for such a question, because of the enormous population of viable secreting units, the expectation of direct interaction between receptor and hormone, and a level of basal secretion sufficiently high to show a range of changes by radioimmunoassay. Monolayer cultures of enzymically dispersed cells were prepared from whole pituitaries of normal Charles River CD male rats, using Eagle's minimal essential medium for growth (Grant, Clark & Rosanoff, 1973). After test